Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC

Biagio Ricciuti shared on X:

“Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC

ctDNA detected in 31% of patients with stage I NSCLC (13% LUAD)
ctDNA detection was predictive of post-surgical G3 tumors, pathological upstaging, increased PD-L1
Decreased RFS and OS in patients with stage I LUAD and detectable pre-surgical ctDNA

ctDNA status may help refine recurrence risk within the clinical stage I bracket in addition to clinical TNM staging.”

Clinical Utility of Tumor-Naïve Pre-surgical ctDNA Detection in Early-stage NSCLC

Authors: Tae Hee Hong, Soohyun Hwang, Abhijit Dasgupta, Chris Abbosh, Tiffany Hung, Jörg Bredno, Jill Walker, Xiaojin Shi, Tsveta Milenkova, Leora Horn, Joon Young Choi, Ho Yun Lee, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Shoujie Chai, Kate Rhodes, Manami Roychowdhury-Saha, Darren Hodgson, Hong Kwan Kim and Myung-Ju Ahn.

Source: Biagio Ricciuti/X

Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.